A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer
NCT02069041
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
8
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Hepatocellular
Interventions
BIOLOGICAL:
Ramucirumab
DRUG:
FOLFOX4
Sponsor
Eli Lilly and Company